联系方式：400-650-8506
CNEN
产品名称 Temozolomide | DNA methylating agent | TMZ | NSC 362856 | SCH 52365 | CCRG 81045 | 97716-75-1 | Temodal | NSC362856 | SCH52365 | CCRG81045 | CAS [85622-93-1] | Axon 2326 | Axon Ligand™ with >100% purity available from stock from supplier Axon Medchem
产品货号 Axon 2326 CAS [85622-93-1] MF C6H6N6O2MW 194.15 Purity: 100% Soluble in 0.1N HCl(aq) and DMSO Description Chemotherapeutic apoptosis inducer. An orally active alkylating agent prodrug, delivering a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). Temozolomide has demonstrated efficacy in the treatment of a variety of solid tumors, primary malignant brain tumors and metastatic melanoma (IC50 value 5 μM for cytotoxicity against mouse TLX5 lymphoma cells).The primary cytotoxic lesion, O6-methylguanine (O6-MeG) can be removed by methylguanine methyltransferase (MGMT; direct repair) in tumours expressing this protein, or tolerated in mismatch repair-deficient (MMR-) tumours. References Certificates Categories Extra info J. Zhang et al. Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 2012, 5, 102-114.   H.S. Friedman et al. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 2000, 6, 2585-2597. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology DNA-damage Response DNA DNA methylating agent; apoptosis inducer Chemical name 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide Parent CAS No. [85622-93-1] Order Size Unit Price Stock 10 mg €50.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

Temozolomide - TMZ | NSC 362856 | SCH 52365 | CCRG 81045

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2326

CAS [85622-93-1]

MF C6H6N6O2
MW 194.15

  • Purity: 100%
  • Soluble in 0.1N HCl(aq) and DMSO

Temozolomide

Description

Chemotherapeutic apoptosis inducer. An orally active alkylating agent prodrug, delivering a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). Temozolomide has demonstrated efficacy in the treatment of a variety of solid tumors, primary malignant brain tumors and metastatic melanoma (IC50 value 5 μM for cytotoxicity against mouse TLX5 lymphoma cells).
The primary cytotoxic lesion, O6-methylguanine (O6-MeG) can be removed by methylguanine methyltransferase (MGMT; direct repair) in tumours expressing this protein, or tolerated in mismatch repair-deficient (MMR-) tumours.
产品资料